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Background: Injection hormonal contraceptive can be distinguished into depomedroxy-
progesterone acetate (DMPA) and combination. DMPA injection is administered in single dose of 
150 mg/mL intramuscular every 12 week. It was hypothesized that DMPA injection resulted 
inadvertent effect such as lowered sexual life quality, increased body mass index, lowered quality of 
skin health, and abnormal uterine bleeding. This study aimed to examine the effects of DMPA 
injection on sexual life, body mass index, skin health, and abnormal uterine bleeding. 
Subjects and Method: This was observational analytical study with retrospective cohort design. 
This study was conducted in Jombang, East Java. A total sample of 149 women of reproductive age 
consisting of 99 DMPA injection contraceptive users and 50 non hormonal contraceptiveusers was 
selected for this study, by stratified random sampling. The dependent variables were sexual life 
quality, body mass index (BMI), skin health, and uterine bleeding. The independent variable was 
DMPA injection contraceptive use and age. The data were collected by a set of questionnaire. 
Sexual life quality was measured by female sexual function index (FSFI). The data were analyzed by 
multiple logistic regression. 
Results: Hormonal contraceptive use (OR= 20.17; 95% CI = 6.62 to 61.42; p<0.001) and age 30-35 
years old (OR= 17.51; 95% CI= 5.74 to 53.38; p<0.001) increased the risk of low quality of sexual life. 
Age 30-35 years old lowered (OR= 0.16; 95% CI= 0.07 to 0.36; p<0.001) low quality of skin health. 
Hormonal contraceptive use (OR= 4.25; 95% CI= 1.95 to 9.30; p<0.001) increased the risk of low 
quality of skin health. 
Conclusion: Hormonal contraceptive use and age 30-35 years increase the risk of low quality of 
sexual life. Age 30-35 years old decreases low quality of skin health but hormonal contraceptive use 
increases the risk of low quality of skin health. 
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Indonesia's population growth rate in 2015 
is alarming because it reaches 1.49% or 
around 4.5 million annually. This growth 
rate will be even more worrying if the birth 
is not qualified, the actual population must 
drop to at least 1.1%, hampered by several 
problems faced by the development of 
population and family planning, including 
the still high population growth compared 
to the conditions that will be achieved by 
1.1%; there is still a high total birth rate 
(TFR) compared to an ideal condition of 2.1 
children per woman of reproductive age 
and disparity (gap) between provinces, 
between rural-urban areas, and between 
socio-economic groups.  
Faster population growth in Indo-
nesia needs to get serious attention from 
the parties concerned, not only from 
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government agencies that handle it, but 
also from the society. If you do not get 
support from the community, especially 
couples of childbearing age, then the pro-
gram of the National Population and 
Family Planning Board specifically for the 
independent family planning movement 
will not be achieved. If this happens, then 
the faster growth cannot be avoided by the 
Indonesian people, which has a negative 
impact on economic growth, increasingly 
narrow employment, etc. 
The lack of success of the self-
planning family movement is most likely 
due to the low and insignificant increase in 
contraceptive use (CPR), and there are still 
disparities between provinces, regions and 
levels of welfare; still less effective in the 
use of long-term contraceptive methods 
such as intrauterine device / IUD, implants, 
female and male surgery methods (MOW 
and MOP), and more use of contraception 
for short periods such as injections and 
pills; still high drop-out rates (including 
failures and complications) in the use of 
short-term contraceptives that most accep-
tors use; the low participation of men in 
family planning. 
According to Data Achievement of 
Estimated Public Demand (PPM), active 
family planning participants in 2015 were 
29,714,498 participants with details of 
condom users of condoms amounting to 
1,099,380 participants (3.70%), MOW 
amounting to 1,663,930 participants 
(5.60%), injections of 15,988,541 partici-
pants (53.81%), IUD was 2,020,490 partici-
pants (6.80%), MOP was 148,560 partici-
pants (0.50%), implants were 2,256,727 
participants (9.59%) and pills were 
6,536,870 participants (22%). In East Java 
today many fertile women (WUS) use 
contraception in the form of injectable birth 
control. Data collected at the East Java 
National Population and Family Planning 
Board (BKKBN) showed the use of inject-
able contraceptives reached 443,110 partici-
pants (59.49%), pill amounting to 156,384 
participants (21%), implant amounting to 
63,918 participants (8.58%), condoms 
amounting to 22,748 participants (3.05%), 
IUD amounting to 45,809 participants 
(6.15%), MOW amounting to 12,864 
participants (1.73%). 
According to Everett (2008), the 
effectiveness of injectable contraception 
between 99% and 100% in preventing preg-
nancy, while according to Uliyah (2008) 
failure in the use of injectable contra-
ceptives is only about 0.3 pregnancies from 
100 users in the first year including DMPA 
(depot medroxcyprogesteroneacetate) and 
combination. DMPA injections contain a 
medroxcyprogesterone acetate depot given 
in a single injection of 150 mg/ml intra-
muscularly (IM) every 12 weeks (Uliyah, 
2010). But the side effects of using inject-
able contraception for a long time accord-
ing to Everett (2008) can cause irregular 
bleeding, amenorrhea, late return to 
fertility to one year, depression, increased 
body weight, and osteoporosis. 
According to Everett (2008), the 
effectiveness of injectable contraception is 
between 99% and 100% in preventing preg-
nancy, while according to Uliyah (2008), 
failure in the use of injectable contracep-
tives is only about 0.3 pregnancies from 
100 users in the first year which are DMPA 
(depot medroxcyprogesterone acetate) and 
combination. DMPA injections contain a 
medroxcyprogesterone acetate depot given 
in a single injection of 150 mg / ml intra-
muscularly (IM) every 12 weeks (Uliyah, 
2010). But the side effects of using inject-
able contraception for a long time accord-
ing to Everett (2008), can cause irregular 
bleeding, amenorrhea, late return to ferti-
lity to one year, depression, increased body 
weight, and osteoporosis.  
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A study by Murniawati and Endang 
(2012), the subjects of the old study using 
new categories amounted to 11 people 
(100%) experienced an increase in body 
weight of 8 people (72.7%) and those who 
did not rise by 3 people (27.3), while the 
research subjects were in the old category 
21 people (100%), gained 21 people (100%). 
According to Irianto (2014), the occurrence 
of weight gain is likely because the hor-
mone progesterone makes it easier to 
change carbohydrates and sugar into fat, so 
that the fat under the skin increases. In 
addition, the hormone progesterone also 
causes appetite to increase and decrease 
physical activity, as a result, of the use of 
injections can cause weight gain.  
At the time of the woman before 
menstruation, they usually will experience 
some problems, one of them is the appear-
ance of acne on the face, this is due to an 
increase in the hormone progesterone 
which makes the skin produce excessive oil, 
so it can support the onset of acne due to 
accumulation of fat in the tissue. According 
to Irianto (2014), hormonal changes caused 
by the use of injectable contraception can 
cause some skin disorders such as the onset 
of acne. 
Based on preliminary studies by inter-
viewing in Jombang Subdistrict, Jombang 
Regency, women of reproductive age 
(WUS) who use injectable contraception> 1 
year, 20 study subjects experienced sexual 
dysfunction in the form of 5 libido 
decreases (25%), this is because they often 
feel pain during intercourse and ultimately 
reduce the sexual desire or arousal, and 
that is associated with an average weight 
gain of 2.7 kg for the first year of use 
amounting to6 people (30%), while those 
who experience skin disorders, such as 
facial acne due to use DMPA contraception 
was 7 people (35%), while the remaining 2 
people (10%) did not experience side effects 
because of the length of use <1 year.  
The mitigation of side effects caused 
by the use of injectable contraceptives is by 
providing counseling to prospective KB 
acceptors about the disadvantages and 
benefits of using contraceptive injections, 
while for participants of the old family 
planning acceptors who used injectable 
contraceptives and experienced side effects 
such as sexual dysfunction in the form of 
decreased libido, weight gain and skin 
health, namely zits need to stop the use of 
injectable contraceptives and consult health 
professionals or clinics.  
 
SUBJECTS AND METHOD 
This was an analytic observational study with 
a cross sectional design. The study was 
conducted in Jombang, East Java, from June 
to August 2016. The population of this study 
were all women of childbearing age who used 
injectable contraceptive contraceptives in 
Jombang District amounting to 9,072 people. 
A sample of 99 women reproductive age was 
selected for this study by stratified random 
sampling. Data on sexual quality was 
measured by female sexual function index 
(FSFI). The other variables were measured by 




1. Univariate analysis 
The results of the description of Table 1 show 
that the characteristics of the research 
subjects were mostly 30-35 years old for 
women of childbearing age amounting to 85 
people (57%), most of them were more than 
high school education amouting to 136 
people (91.3%) and worked amounting to 90 
people (90.4%). 
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Table 1. The frequency distribution of 
study subject characteristics 
Characteristics n % 
Age   
20-29 years 64 43.0 
30-35 years 85 57.0 
Education   
Primary school (< SHS) 13 8.7 
Secondary school (≥SHS) 136 91.3 
Occupation   
Not working 59 39.6 
Working 90 60.4 
 
Based on the results in Table 2, it is 
known that most are hormonal contracep-
tives which consisted of 81 people (54.4%), 
sexual life has 86 people (57.7%), 96 people 
gain weight (64.4%), acne skin health of 93 
people (62.4%), and abnormal bleeding is 89 
people (40.3%).  
Table 3 presents the results of biva-
riate analysis of age with sexual life (OR= 
7.64; 95% CI= 3.66 to 15.93; p<0.001). This 
shows that there is a negative and signi-
ficant relationship between age and sexual 
life in women of childbearing age. 
The relationship between the varia-
bles of type of contraception and sexual life 
(OR= 9.09; 95% CI= 4.29 to 19.26; p 
<0.001). It shows that there is a negative 
and significant relationship between types 
of contraception and sexual life in women 
of childbearing age. 
Table 4 presents a bivariate analysis 
of age with skin health (OR= 0.21; 95% CI = 
0.10 to 0.46; p<0.001). It shows that there 
is a positive and significant relationship 
between age and skin health in women of 
childbearing age.  
Table 2. Samples Description 
Variable n % 
Type of Contraception   
Non Hormonal   68 45.6 
Hormonal   81 54.4 
Sexual Life   
No disorder 63 42.3 
With disorder 86 57.7 
Body mass index    
Not gain 53 35.6 
Gain 96 64.4 
Skin Health   
No acnes 56 37.6 
Acnes 93 62.4 
Abnormal Uterine Bleeding   
Normal  60 59.7 
Abnormal  89 40.3 
 
Table 3. Chi-square test of the relationship between age and type of injection 











Age       
20-29years 44(68.8%) 20(31.3%) 7.64 3.66 15.93 <0.001 
30-35 years 19(22.4%) 66(77.6%)     
Type of 
contraception 
      
Non hormonal 47(69.1%) 21(30.9%) 9.09 4.29 19.26 <0.001 
Hormonal 16(19.8%) 65(80.2%)     
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There was a positive and significant 
relationship between types of contraception 
and skin health in women with reproductive 
age (OR= 3.03; 95% CI= 1.52 to 6.03; 
p<0.001).  
Analysis on variables of age, type of 
contraception, abnormal uterine bleeding, 
and bady mass index were conducted using 
the Pearson product moment test. 
Table 5 presents a the bivariate 
analysis of age with abnormal uterine 
bleeding, obtained Pearson correlation (r) 
value of 0.22 with p = 0.007. This shows that 
there is a positive and significant relationship 
between age and abnormal uterine bleeding 
in women of childbearing age. 
In the variable type of contraception 
with abnormal uterine bleeding, a Pearson 
correlation (r) value was 0.71 with p <0.001. 
This shows that there is a positive and 
significant relationship between types of 
contraception and abnormal uterine bleeding 
in women of childbearing age. 
Table4. Chi-square test of the relationship between age and type of injection 






No disorders Disorders Lower Limit Upper Limit 
Age       
20-29 years 12(18.8%) 52(81.3%) 0.21 0.10 0.45 <0.001 
30-35 years 44(51.8%) 41(48.2%)     
Type of Contraception       
Non hormonal 35(51.5%) 33(48.5%) 3.03 1.52 6.02 <0.001 
Hormonal 21(25.9%) 60(74.1%)     
 
Table 5. Pearson product moment test of relationship between age and hormonal 




Abnormal uterine bleeding The age of 30-35 years 0.22 0.007 
 Hormonal 0.71 <0.001 
Body mass index The age of  30-35 years 0.53 <0.001 
 Hormonal 0.59 <0.001 
 
The relationship of age variables with 
body mass index, the pearson correlation 
(r) was 0.53 and p <0.001. This shows that 
there is a positive and significant relation-
ship between age and abnormal uterine 
bleeding in women of childbearing age. The 
relationship of the variable type of contra-
ception with the body mass index, the 
pearson correlation (r) was 0.59 and p 
<0.001. This shows that there is a positive 
and significant relationship between the 
types of contraception with body mass 
index in women of childbearing age. 
 
Table 6. Results of logistic regression analysis of age and hormonal contraception 
with impaired quality of sexual life at women of childbearing age 
Independent Variable OR 
CI (95%) 
p Lower Limit Upper Limit 
Age 17.51 5.74 53.38 <0.001 
Hormonal contraception 20.17 6.62 61.42 <0.001 
N Observation = 149 
-2 log likelihood = 125.336 
Nagelkerke R-Square  = 0.546 
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Table 6 shows that there is a statistically 
significant relationship between age and 
quality disorders of sexual life experiencing 
disturbances (OR= 17.51; 95% CI= 5.75 to 
53.39; p<0.001). The older people are, the 
more (17.52 times) they experience sexual 
health problems. There was a statistically 
significant relationship between types of 
contraception with quality disorders of sexual 
life experiencing disturbances (OR= 20.17; CI 
95% 6.62 to 61.42; p<0.001). Hormonal 
contraception is 20.17 times having a disrup-
tion in sexual life. Nagelkerke's R Square 
value is 54.6%, this indicates that the varia-
bility of the dependent variable that can be 
explained by the independent variable is 
54.6% while the remaining 45.4% is explain-
ed by the variability of other variables outside 
the two independent variables examined. 
Table 7. The results of logistic regression analysis between age, hormonal 
contraception, and skin health disorders in women of childbearing age 
Independent Variabel OR 
95% CI 
p 
Lower Limit Upper Limit 
The age of 30-35 years 0.16 0.07 0.36 <0.001 
Hormonal Contraception 4.25 1.95 9.30 <0.001 
N Observation= 149 
-2 log likelihood= 104.95 
Nagelkerke R-Square= 26% 
 
Table 7 shows the results of logistic 
regression analysis, there is a statistically 
significant relationship between age with skin 
health experiencing acne (OR = 0.16; 95% CI 
= 0.07 to 0.36; p <0.001). The older the age 
in, the higher the probability of experiencing 
acnes is (0.16 times). There was a statistically 
significant relationship between types of 
contraception with skin health experienced 
by jewels (OR = 4.25; 95% CI = 1.95 to 9.30; 
p <0.001). Type of hormonal contraception 
20.16 times experiencing acne. Nagelkerke's 
R Square value is 0.26, this indicates that the 
variability of the dependent variable that can 
be explained by the independent variable is 
26% while the remaining 74% is explained by 
the variability of other variables outside the 
two independent variables examined. 
Table 8. Linear regression between age and hormonal contraception with 
abnormal uterine bleeding in women of childbearing age 
Independent Variable B SE p 
Constant 6.09 0.21 <0.001 
Hormonal Contraseption 2.93 0.23 <0.001 
The age of 30-35 years 0.70 0.24 <0.001 
N Observation = 149  
Adjusted R square = 52%  
 
Table 8 shows the adjusted R square 
value= 52.6%, this indicates that the 
variability of the dependent variable that can 
be explained by the independent variable is 
52.6% while the remaining 47.4% is 
explained by the variability of other variables 
outside the two independent variables 
examined. 
The results of the linear regression equation 
are described as follows. 
1. Injection (hormonal) contraception affects 
2.93 of abnormal abnormal bleeding and 
is statistically significant (p<0.001). 
2. Age affects 0.70 to abnormal uterine 
bleeding and is statistically significant 
(p<0.001). 
Table 9 shows that the adjusted R 
square= 58.5%, this indicates that the 
dependent variable variability that can be 
explained by the independent variable is 
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58.5% while the remaining 41.5% is 
explained by the variability of other varia-
bles outside the two independent variables 
studied. 
The results of the linear regression 
equation can be described as follows. 
1. Injectable (hormonal) contraception 
affects 5.75 against the body mass index 
(BMI) and is statistically significant (p 
<0.001). 
The older the age is, the bigger the 
amount of 5.05 to abnormal uterine 
bleeding. Statistically, the relationship was 
stated to be significant (p <0.001). 
Table 9. Variable linear regression results for age and hormonal contraception 
with body mass index for women of childbearing age 
Independent Variable b SE p 
Constant 21.90 0.49 <0.001 
Hormonal Contraseption 5.75 0.54 <0.001 
The age of30-35 years 5.05 0.55 <0.001 
N Observation= 149  
Adjusted R square= 58%  
 
DISCUSSIONS 
1. The relationship between the effec-
tiveness of injection contraceptive 
use and the quality of sexual life 
Injection contraceptive was divided into 
two groups, namely the progestin group 
and the progestin group with estrogen-
propionate mixture (Saifuddin, 2010). One 
of the side effects of using injection contra-
ceptive was the change in libido or sexual 
drive. Symptoms of a decrease or increase in 
sexual drive (libido). The decreased libido 
was due to the effects of progesterone, espe-
cially those which contained 19-progression 
that caused a dry vaginal. However, psycho-
logical factors could also affect this occur-
rence. Increased or decreased libido was 
very subjectively, therefore, these symp-
toms must be monitored carefully to ensure 
that the client has decreased or increased 
libido. Changes in libido can also be 
influenced by psychological factors (Irianto, 
2014).  
The result of this study revealed that 
there was a meaningful relationship 
between the effect of injection contracep-
tive and the quality of sexual life among 
women in reproductive age in Jombang 
District, and the level of relationship was low. 
This relationship has a positive pattern, 
meaning that the long-term use of injection 
contraceptive could increase the sexual 
quality disorders. The use of hormonal 
contraception could lead to sexual dys-
function for its users due to the hormone-
content contained in it.  
The use of hormonal contraceptives 
that contained a combination of both hor-
mones, estrogen and progestin, or which 
contained only one of the hormones, has a 
significant role in the incidence of sexual 
dysfunction. However, the hormonal con-
traceptive use that contained a combination 
of both hormones was more significant in 
causing sexual dysfunction compared to 
hormonal contraception which only con-
tained one hormone, this was in line with a 
study done by Saputra (2013) which stated 
that comparison of the sexual dysfunction 
incident according to FSFI scoring on IUD 
and hormonal acceptors at Rajabasa Bandar 
Lampung Health Center stated that there 
were significant differences in the incidence 
of sexual dysfunction of hormonal and IUD 
acceptors, where the incidence of hormonal 
acceptor sexual dysfunction was higher than 
IUD acceptors, and the incidence of 
hormonal sexual dysfunction was higher than 
IUD.  
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From the results of the frequency 
distribution of sexual quality in women of 
reproductive age, it was found that women 
of reproductive age did not experience 
higher disorders than those who expe-
rienced disorders.Women in reproductive 
age who experience disorders of more than 
half of the study subjects used 3-month 
injection contraceptives, while less than 
half of the subjects used 1-month injection 
contraceptives. Therefore, it was concluded 
thatthe use of Depo Provera injection con-
traceptive which contained DMPA (Depo 
Medroxyprogesteron Acetate) and it was 
given in every three months could lead to 
sexual quality disorders, this was in accord-
ance with a study done byBatlajery (2015) 
which stated thatthe largest presentation of 
sexual dysfunction occurred in women who 
used the contraceptive method of DMPA 
injection (3-month injection) compared to 
women who used non-DMPA contraceptive 
methods. According to Yunardi, et al. 
(2009) in a study done by Batlajery (2015) 
it was stated that DMPA injections only 
contained the progesterone hormone which 
has the main effect to prevent ovulation 
with high levels of progestin which would 
actively inhibit the LH (Luteinizing Hor-
mone) surge. This would eventually lead to 
sexual dysfunction in the form of decreased 
libido and other sexual potentials.  
2. The relationship between the 
effectiveness of injection contra-
ceptive use and body mass index  
One of the side effects of injection contra-
ceptives was weight changes. The symptoms 
of the average weight gain for each year 
varies between 2.3-2.9 kg of weight gain, it 
was probably caused by the progesterone 
hormone which help to change the 
carbohydrates and sugar into fat, so that 
the fat under the skin increased. In addi-
tion, the progesterone hormone also 
increased the appetite and reduced physical 
activity (Irianto, 2014). The debate about 
the enhancement of weight as a result of 
continuous use of DMPA-IM, as well as 
increasing the amount of weight reported to 
increase over time, from about 1-2 kg after 1 
year of utilization to 4-10 kg after a long 
utilization of around 3 -5 years. According 
to WHO, in investigating the side effects 
and the reasons for discontinuation of 
DMPA-IM, it was found that women gained 
an average of 1.9 kg in the first year of 
DMPA-IM use, and body weight was quoted 
as one of the main reasons for the disconti-
nuing use of DMPA-IM. (Sari, 2015). 
The result of this study found that 
there was a relationship between the effect 
of injection contraceptive use and body 
mass index among women in reproductive 
age with an adequate level of relationship. 
This relationship has a positive pattern, 
meaning that the long-term use of injection 
contraceptives would increase the body 
mass index for about 2.5 kg on average. The 
use of hormonal contraceptives could lead 
to various side effects, one of them was the 
change in body weightacceptor. This was 
caused by the progesterone hormone which 
facilitated the changes in carbohydrates 
and sugar into fat, so that the fat under the 
skin tissue increased.  
Weight gain was one of the side 
effects that were often complained of by 
hormonal contraceptive acceptors, espe-
cially hormonal injection contraceptives of 
Depo Medroxy Progesterone Acetate Con-
traceptive. This study was consistent with a 
study by Sriwahyuni and Wahyuni (2009) 
which stated that there was no significant 
relationship between the duration of hor-
monal contraceptive use and weight gain. 
This mean that the long-term used of 
hormonal contraception could increase the 
body weight. From the results of the fre-
quency distribution of body mass index in 
women of reproductive age, it was found 
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that most of the women of reproductive age 
experienced weight gain, while a small 
proportion of the research subjects did not 
experience weight gain. 
Women reproductive age who expe-
rienced weight gain usually used 3-month 
injection contraceptive than 1-month inject-
ion contraceptive, this study was consistent 
with a study by Sari (2015) which stated that 
DMPA hormonal injection contraceptives 
were the only hormonal contraception that 
was consistently associated with weight gain. 
A prospective study found that women who 
used Depo-Provera gained an average weight 
of 5.1 kg for 36 months, while women who 
used combined oral contraceptives did not 
gain any weight. 
3. The relationship between the 
effectiveness of injection contra-
ceptive use and skin health 
Injection contraceptive was divided into 
two groups: progestins and progestins with 
esterogenpropionate mixtures (Saifuddin, 
2010). One of the side effects of using 
injection contraceptive was acne changes. 
The cause of acne was an enhancement in 
fat levels in Norprogestin-19 and the cause 
of weight gain occurred due to the pro-
gesterone hormone which help the process 
of changing the carbohydrates and sugar 
into fat, so that the fat under the skin 
increased (Irianto, 2014).  
According to Suyono (2002) in Asva 
(2015), physiological amounts of proges-
terone have no effect on the effectiveness of 
the fat glands. Sebum production remained 
during the menstrual cycle, but sometimes 
progesterone could cause premenstrual 
acne. 
The result of this study found that 
there was a relationship between the effect 
of injection contraceptive use and women’s 
skin health with a low level of relationship. 
This relationship has a positive pattern, 
meaning that the long-term use of injection 
contraceptive would cause the occurrence 
of acne on the skin. The effect of injection 
contraceptives on skin health lead to the 
occurrence of acne vulgaris (acne). 
Acne vulgaris (acne) was caused by 
estrogen and progesterone. Estrogen has no 
effect on sebum production. Estrogen could 
reduce the gonadotropin levels from the 
pituitary gland. The gonadotropin hormone 
has the effect of reducing sebum produc-
tion, whereas sebum was an oily substance 
that mainly consisted of fat, keratin, and 
cellular ingredients produced by sebaceous 
glands in the skin. Physiologically, it has no 
effect on the effectiveness of the fat glands 
in progesterone. Sebum production re-
mained during the menstrual cycle, but 
sometimes progesterone could cause pre-
menstrual acne.  
This study was consistent with a study 
by Kansil (2015) which stated that there 
was a relationship between injection con-
traceptive use ofdepo medroksi progesteron 
Asetat (DMPA) on physiological changesof 
WRA in Ranomuut health center, Manado. 
There was a relationship between DMPA 
injection contraceptive andphysiological 
changes such as body weight enhancement, 
acnes, and headaches among women 
reproductive age at Ranomuut Health Center 
in Manado.  
From the result of frequency distri-
bution, it was known thatmore than half of 
the study subjects did not have acne and 
less than half of the research subjects had 
acne. Women of reproductive age who used 
injection contraceptive for 3 months were 
more likely to have acne compared to 
women of reproductive age who used injec-
tion contraceptive for 1 month. Therefore, 
more than half of women in reproductive 
age who experienced acne used 3-month 
injection contraceptive. 
Depo Provera content which con-
tained DMPA (Depo Medroxyprogesterone 
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Acetate) given once in every 3 months could 
give the side effects of acne, this was in line 
withRahmawati and Sukanto (2012) who 
stated thatthe progestins contained in oral 
contraceptives include estranges and gona-
nes which were derivatived of 19-nortes-
tosterone, cyproterone acetate, the latest 
progestin, and drosperinone. Estrane 
groups (norethindrone, noretindron asetat, 
etinodiol diasetat) and gonane (norgestrel, 
levonorgestrel, desogestrel, gestoden, norges-
timate) could increase the effect of andro-
genic and stimulated the occurrence of acne, 
hirsutism, and androgenic alopecia. This 
progestin could also lead to changes in lipid 
metabolism and could increase serum 
glucose.  
While according to a study done by 
Maria, et al., (2016) it was stated that acne 
side effect could also be caused by the 
maternal diet which did not pay much 
attention to the consumption of foods that 
contained lots of fat. In addition, it can also 
be caused by improper use of cosmetics or 
cosmetic allergies. 
4. The relationship between the 
effectiveness of injection contra-
ceptive use and abnormal uterine 
bleeding 
Side effects of injection contraceptive 
include menstrual cycle disorders. The 
symptoms or complaints including not 
having menstruation (amenorrhea), bleed-
ing in the form of droplets or patches 
(spotting), bleeding outside the menstrual 
cycle (metroragia), longer and/or more 
than usual menstrual bleeding. The cause 
was due to hormonal imbalances so that the 
endometrium experienced histological 
changes, the condition of amenorrhea was 
caused by endometrial atrophy (Irianto, 
2014). Bleeding from the corpus uteri 
include all menstrual abnormalities in 
terms of both number and duration. This 
was described as chronic if it was happened 
for the majority of the previous 6 months, 
and acute if it was a severe bleeding which 
required rapid treatment or intervention. 
Clinical manifestations could be in a 
condition of enormous bleeding, a little 
bleeding, an extended or irregular mens-
trual cycle (Bazaid et al., 2011).   
The result of this study revealed that 
there was a relationship between the effect 
ofinjection contraceptive use and abnormal 
uterine bleeding among women in repro-
ductive agewith a strong level of relation-
ship. This relationship was positive, it mean 
that the long-term use of injection contra-
ceptives would increase the incidence of 
abnormal uterine bleeding. Bleeding due to 
injection contraceptive use could occur in 
combined contraceptive pills (CCP) users, 
injections of depo medroxy progesterone 
acetate (DMPA). Bleeding in CCP users and 
DMPA injections mostly occurred due to 
interrupted bleeding.  
This was in line with a study done by 
Monica and Mary (2016) which stated that 
subcutaneous DMPA and DMPA intra-
muscular injection also showed the similar 
effect beside body weight and changes in 
bleeding pattern, while a study of Firoozeh 
and Maryam (2013) stated that women 
aged 18-40 years old used Depo-Medroxy 
progesterone acetate (DMPA) or Cyclofem. 
One of the DMPA side effects was irregular 
bleeding, and the side effect in the Cyclo-
fem group was also irregular bleeding. 
Bleeding pattern changes were the most 
important problem that lead to the second 
termination of contraceptive methods in 
participants.  
From the result of frequency distri-
bution, it was known that from the abnor-
mal uterine bleeding, it can be concluded 
that menstrual bleeding with 2 pads of 
blood occurred outside the cycle for <7 days 
and >12 days. This was in line with a study 
done by Nelson (2010) which stated thatthe 
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users of levonorgestrel intrauterine system 
decreased to 30 ml of blood loss, whereas 
those who used medroxyprogesterone acetate 
achieved a reduction to 136 ml. The effective-
ness of each therapy continued to increase 
over time. At the closing of the study at 6 
months, median menstrual blood loss in 
women who used the levonorgestrel 
intrauterine system was only 7 ml, whereas in 
women who used medroxyprogesterone 
acetate was 121 ml.  
5. The relationship between injection 
contraceptive use, age, employment, 
and activity with sexual life  
Analysis of the relationship between inde-
pendent variables of the use of injection 
contraceptives effectiveness, age, employ-
ment, and length of activity with sexual life 
on women of reproductive age by using 
linear regression test showed that one of 
the the four variables which related to 
sexual life of women in reproductive age 
was age. Age variables in women of repro-
ductive age have a significant relationship 
which mean that the increased age of 
women reproductive age would affect the 
sexual life.  
This study was consistent with a study 
by Batlajery (2015), which stated that 
women who have the reproductive organs 
which were functioned properly were 
around the ages of 20-45 years old. Over 
the age of 50 years old, there can be pro-
blems in sexual activity because they were 
getting older, got more work, and even 
various diseases such as high blood pres-
sure, diabetes, reduced libido or impotence 
(Manuaba, 2009).  
The frequency of sexual activity 
(coitus) was widely varied on average of 1-4 
times a week for people aged 30-40 years 
old. Coitus became increasingly rare with 
the enhancement of age. In women, the 
libido increased in the reproductive period 
until the age of 35 years old, then it stayed 
until the age of 45 years old, and it could 
last after menopause. In men, the peak of 
libido was achieved at the age of 20-30 
years old and the libido lasted until the age 
of 50 years old, and then it slowly reduced, 
but it remained in the body until they 
became elderly (Irianto, 2014).  
6. The relationship between injection 
contraceptive use, age, and educatio 
with body mass index  
Analysis of the relationship between inde-
pendent variables of the use of injection 
contraceptives effectiveness, age, and edu-
cation withbody mass indexamong women 
in reproductive age by using linear regres-
sion test showed that the variables which 
related to body mass index in women of 
reproductive age were the effectiveness of 
injection contraceptive use and education. 
Education variable has a significant rela-
tionship by 0.512, which mean that the 
increased women education would affect 
the enhancement of body mass index. 
Weight gain in the study was largely due to 
hormonal in injection contraceptived, so 
the long-term use of injection contraceptive 
has the potential to increase body weight.  
According to Sriwahyuni (2012), the 
use of hormonal contraceptives which were 
the most widely used by study subjects at 
every level of education was injection. The 
use of pills and implants was most widely 
used by research subjects in a high school 
education level. Knowledge about contra-
ceptive methods has an impact on the 
selection of contraception types so that it 
indirectly influenced the behavior of the 
user. 
The effectiveness of injection contra-
ceptive use variable has a significant rela-
tionship. This mean that the effectiveness 
of long-term use of injection contraceptive 
in women of reproductive age would 
increase the body mass index. This was in 
line with a study done by Kansil (2015) 
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which stated that there was an effect of The 
duration of Depo Provera injection contra-
ceptives use on the side effects of weight 
gain. In addition, the progesterone hor-
mone also caused appetite enhancement 
and decreased physical activity, therefore, 
the use of injections could lead to weight 
gain (Irianto, 2014; Sari, 2015).    
7. The relationship between injection 
contraceptive use and age with skin 
health  
Analysis of the relationship between inde-
pendent variables with gross motor skills 
among toddlers by using logistic regression 
test showed that there was no statistically 
significant relationship between the effec-
tiveness of the use of short-term injection 
contraceptives and skin health of acne 
occurrence.  
This study was not consistent with a 
study by Suyono (2002) in Asva (2015), 
which stated that one of the causes of acne 
occurrence in skin health was progesterone. 
Progesterone, in physiological amounts has 
no effect on the effectiveness of fat glands. 
Sebum production remained during the 
menstrual cycle, but sometimes progeste-
rone could cause pre-menstrual acne. In 
addition, the result of this study was not in 
line with a study done by Kansil (2015) 
which stated that there was a relationship 
between DMPA injection contraceptive and 
physiological changes such as increased 
weight, acne, and headaches in women of 
reproductive age. 
8. The relationship between injection 
contraceptive use, employment, and 
activity with abnormal uterine 
bleeding 
Analysis of the relationship between 
injection contraceptives use, employment, 
and the activity with abnormal uterine 
bleeding among women in reproductive 
ageby using linear regression test. It was 
found that the variables which associated 
with abnormal uterine bleeding in women 
of reproductive age were the effectiveness 
of injection contraceptive use and age. Age 
variable in women of reproductive age has a 
significant relationship by of 0.41, which 
mean that the increased age of women in 
reproductive age would affect abnormal 
uterine bleeding. However, in this study, 
there was a variable that caused abnormal 
uterine bleeding, namely the effectiveness 
of the use of injection contraceptives. From 
the results of data analysis, the effective-
ness of injection contraceptive use variable 
has a significant relationship by 0.91, which 
mean that the effectiveness of long-term 
use of injection contraceptive in women of 
reproductive age would affect abnormal 
uterine bleeding. 
This was in line with Rifki (2016) and 
Bazaid et al. (2011) who stated that bleed-
ing due to counter-septic side effects could 
occur in combined contraceptive pills (CCP) 
users, and injections of depo medroxy pro-
gesterone acetate (DMPA). Bleeding in CCP 
users and DMPA injections mostly occurred 
due to interrupted bleeding. Chlamydia or 
Neisseria infections could also cause 
bleeding in CCP users.   
The results of this study can be con-
cluded that there was an effect of injection 
contraceptive use on sexual life, body mass 
index, skin health, and abnormal uterine 
bleeding in women of reproductive age. The 
results of this study can be used to improve 
understanding of the side effects caused by 
long-term use of injection contraceptives, 
such as the sexual quality of the partner, 
body mass index, and skin health. There-
fore, people can choose the appropriate 
contraceptive method.  
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